The National Cancer Institute (NCI) awarded a $356,850 Cooperative Agreement (CFDA 93.395 - Cancer Treatment Research) to Oregon Health & Science University (OHSU) to characterize the pre-analytical steps involved in blood and bone marrow biopsy sample handling and storage/retrieval for functional assay reporting. The project aims to establish pre-analytical sample processing guidelines to enable maximal reproducibility for functional testing outcomes, including high throughput-drug...
The National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) awarded a $5,684,025 Project Grant under the Diabetes, Digestive, and Kidney Diseases Extramural Research program (CFDA 93.847) to the University of Georgia Research Foundation, Inc. The 5-year grant will fund the establishment of the National Biorepository and Resource for Pituitary Neuroendocrine Tumor Translational Research (BIOPITNET). BIOPITNET aims to create a large-scale biorepository and classification system to...
This Project Grant award from the National Cancer Institute's Cancer Treatment Research program (CFDA 93.395) provides $159,574 to the University of Kansas Medical Center Research Institute, Inc. (KUMCRI) to increase access and participation to early phase clinical trials for underrepresented populations, including veterans. The project aims to develop sustainable strategies to extend access and boost participation in the Experimental Therapeutics Clinical Trials Network (ETCTN) clinical...
The U.S. National Institutes of Health (NIH) awarded a $5,110,455 Cooperative Agreement under the Trans-NIH Research Support program (CFDA 93.310) to develop the Down Syndrome Biorepository (DS-Biorepository) as part of the NIH INCLUDE project. This 5-year award, effective September 30, 2024, will establish a centralized biorepository to support a wide range of research investigations on Down syndrome, including studies on co-occurring conditions such as heart defects, autism, seizures,...
The Defense Health Agency awarded a $3,644,169 Project Grant to the ECOG-ACRIN Medical Research Foundation, Inc. to advance precision and equity in breast cancer care. This funding, provided through the Military Medical Research and Development program (CFDA 12.420), supports a 4-year clinical research extension to the TAILORx study, which aims to improve personalized treatment for breast cancer patients. As a subrecipient, the Foundation has also supported research at Dana-Farber Cancer...
This federal Project Grant award from the National Cancer Institute's Cancer Detection and Diagnosis Research program (CFDA 93.394) provides $440,287 to GE Medical Systems Information Technologies, Inc. to establish a simplified and accessible procedure for multi-analyte simultaneous extraction of DNA, RNA, and protein from tumor touch imprints. This approach aims to democratize cancer biobanking by enabling multi-parametric analysis of smaller tumor samples, including genomic, gene...
This federal Cooperative Agreement award of $686,993 from the National Cancer Institute (NCI) under the Cancer Cause and Prevention Research (CFDA 93.393) program supports research on "Electronic Health Record (EHR)-Based Implementation Strategies and Decision Support for Hereditary Breast and Ovarian Cancer (HBOC) Genetic Testing Among Multiethnic Women (ELISABETH)." The project aims to improve utilization of HBOC genetic testing, particularly among underserved populations, by...
The National Institutes of Health (NIH) Office of the Director awarded a $975,027 Cooperative Agreement under the Trans-NIH Research Support program (CFDA 93.310) to The George Washington University. The project, titled "Enhancing and Making Biomarker Knowledge FAIR Using Contextual CFDE Data", aims to refine and populate a biomarker data model through a partnership with the NCI-supported Early Detection Research Network (EDRN). The initial focus is on cancer biomarker data, with plans...
The National Cancer Institute (NCI) awarded a $401,113 Cooperative Agreement under the Cancer Treatment Research Program (CFDA 93.395) to the University of Washington (UW) to develop a novel "MetaboCore" assay for rapid assessment of drug sensitivity in solid tumor needle biopsies. The goal is to create a robust standard operating procedure (SOP) to evaluate how pre-analytical conditions affect assay performance, including factors like biopsy needle type, transport solution, culture...
The National Cancer Institute (NCI) awarded a $417,236 Cooperative Agreement under the Cancer Cause and Prevention Research (CFDA 93.393) program to Case Western Reserve University (CWRU) to develop the Population Cancer Assessment and Surveillance Engine (POP-CASE), a transportable informatics tool that integrates patient-level cancer registry data with granular community-level data. The project aims to: 1) build the POP-CASE database and computational layer using an extended set of community...